|
|
News Breaks | | | | September 28, 2012 | | 09:44 EDT |  | ACHN, GILD | Deutsche Bank's biotech analyst to hold a conference call
Biotech Analyst Karnauskas discusses Gilead Sciences and the HCV market and research and development for Achillion Pharmaceuticals on an Analyst/Industry conference call on September 28 at 10 am. | |
|
News For ACHN;GILD From The Last 14 Days Check below for free stories on ACHN;GILD the last two weeks. |
|
|
| May 21, 2013 | | 16:51 EDT |  | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
 Subscribe for More Information | | | May 20, 2013 | | 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | 10:30 EDT | | ACHN | Achillion management to meet with Maxim
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | | | May 7, 2013 | | 06:08 EDT |  | ACHN | Achillion reports Q1 EPS (14c), consensus (15c)
Subscribe for More Information | |
|
|
|
|
|
|
